BiotechTube

RHB-102 + Placebo Oral Tablet

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastroenteritis

Conditions

Gastroenteritis, Gastritis

Trial Timeline

Dec 8, 2014 → Feb 16, 2017

NCT ID
NCT02246439

About RHB-102 + Placebo Oral Tablet

RHB-102 + Placebo Oral Tablet is a phase 3 stage product being developed by RedHill Biopharma for Gastroenteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02246439. Target conditions include Gastroenteritis, Gastritis.

What happened to similar drugs?

1 of 10 similar drugs in Gastroenteritis were approved

Approved (1) Terminated (1) Active (8)
🔄mRNA-1403ModernaPhase 3
❌Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)MerckPhase 3
🔄Rotavirus Vaccine, Live, Oral, PentavalentMerckPhase 3
🔄RotaTeq (V260) + IPVMerckPhase 3
🔄V260 + Placebo to V260 + OPV + DTaPMerckPhase 3
🔄Prulifloxacin + PlaceboMerckPhase 3
🔄RotaTeq™ experimental formulation + RotaTeq™ existing formulationMerckPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02246439Phase 3Completed

Competing Products

20 competing products in Gastroenteritis

See all competitors
ProductCompanyStageHype Score
mRNA-1403ModernaPhase 2
0
mRNA-1403ModernaPhase 3
0
Placebo + HIL-214HilleVaxPhase 1
19
HIL-214 + PlaceboHilleVaxPhase 2/3
28
HIL-214HilleVaxPhase 2
25
HIL-214 + PlaceboHilleVaxPhase 2/3
20
Benralizumab + PlaceboAstraZenecaPhase 2/3
38
Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)MerckPhase 3
32
Rotavirus VaccineMerckPre-clinical
18
Rotavirus Vaccine, Live, Oral, PentavalentMerckPhase 3
40
RotaTeq (V260) + IPVMerckPhase 3
40
V260 + Placebo to V260 + OPV + DTaPMerckPhase 3
40
Prulifloxacin + PlaceboMerckPhase 3
40
Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo + Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: PlaceboMerckPhase 1
29
RotaTeq™ experimental formulation + RotaTeq™ existing formulationMerckPhase 3
40
prulifloxacinMerckPhase 3
40
montelukastMerckPre-clinical
26
Bacillus ClausiiSanofiPhase 3
40
Bacillus clausii + Oral Rehydration TherapySanofiApproved
43
VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine TabletVaxartPhase 1
19